Biblio

Filters: Author is Alousi, Amin [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

C

Pidala, J.A., Hamilton, B.K., Martin, P.J., Onstad, L., Storer, B.E., Palmer, J., Alousi, A., Cutler, C., Jagasia, M.H., Chen, G.L., et al. (2019). The Chronic Graft-vs.-Host Disease Failure-Free Survival (cGVHD-FFS) index.Biol Blood Marrow Transplant.

D

Nieto, Y., Valdez, B.C., Thall, P.F., Jones, R.B., Wei, W., Myers, A., Hosing, C., Ahmed, S., Popat, U., Shpall, E.J., et al. (2016). Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.Cancer.

H

Srour, S.A., Saliba, R.M., Bittencourt, M.Cb, Perez, J.Miguel Ram, Kongtim, P., Alousi, A., Al-Atrash, G., Olson, A., Betul, O., Mehta, R., et al. (2019). Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.Am J Hematol.

I

Saini, N.Y., Saliba, R.M., Rondon, G., Maadani, F., Popat, U., Hosing, C.M., Betul, O., Bashir, Q., Olson, A., Nieto, Y., et al. (2019). Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma.Biol Blood Marrow Transplant.

Hamilton, B.K., Liu, Y., Hemmer, M.T., Majhail, N., Ringdén, O., Kim, D., Costa, L., Stuart, R., Alousi, A., Pidala, J.A., et al. (2019). Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.

N

Kongtim, P., Hasan, O., Perez, J.Miguel Ram, Varma, A., Wang, S.A., Patel, K.P., Chen, J., Rondon, G., Srour, S., Bashir, Q., et al. (2019). A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.

P

Alousi, A., Wang, T., Hemmer, M.T., Spellman, S.R., Arora, M., Couriel, D.R., Pidala, J., Anderlini, P.N., Boyiadzis, M., Bredeson, C.N., et al. (2018). Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival.Biol Blood Marrow Transplant.

Kebriaei, P., Singh, H., M Huls, H., Figliola, M.J., Bassett, R., Olivares, S., Jena, B., Dawson, M.J., Kumaresan, P.R., Su, S., et al. (2016). Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.J Clin Invest.

Turcotte, L.M., Wang, T., Hemmer, M.T., Spellman, S.R., Arora, M., Yingst, A., Couriel, D., Alousi, A., Pidala, J., Knight, J.M., et al. (2018). Pro-inflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes.Biol Blood Marrow Transplant.

Aung, F.M., Lichtiger, B., Rondon, G., C Yin, C., Alousi, A., Ahmed, S., Andersson, B., Bashier, Q., Ciurea, S.O., Hosing, C., et al. (2016). Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.Biol Blood Marrow Transplant.

R

Gaballa, S., Ge, I., Fakih, R.El, Brammer, J.E., Kongtim, P., Tomuleasa, C., Wang, S.A., Lee, D., Petropoulos, D., Cao, K., et al. (2016). Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Cancer.

V

Nieto, Y., Valdez, B.C., Thall, P.F., Ahmed, S., Jones, R.B., Hosing, C., Popat, U., Shpall, E.J., Qazilbash, M., Gulbis, A., et al. (2015). Vorinostat Combined with High-Dose Gemcitabine, Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphomas.Biol Blood Marrow Transplant.